OnKure Therapeutics (NASDAQ:OKUR) Price Target Cut to $34.00 by Analysts at HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR) had its target price lowered by HC Wainwright from $40.00 to $34.00 in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts have also issued reports on OKUR. Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They set an “outperform” rating and a $33.00 price target for the company. Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. Finally, Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Trading Up 1.9 %

Shares of NASDAQ OKUR opened at $4.91 on Tuesday. The firm’s fifty day moving average price is $5.60. The company has a market cap of $65.97 million, a price-to-earnings ratio of -0.40 and a beta of 0.28. OnKure Therapeutics has a 1 year low of $4.45 and a 1 year high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). On average, analysts predict that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Large investors have recently modified their holdings of the stock. Barclays PLC bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth $75,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at $104,000. Walleye Capital LLC purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at $116,000. Two Sigma Advisers LP purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at $122,000. Finally, Shay Capital LLC purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at $129,000. 90.98% of the stock is owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.